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Abstract
Background: Several symptoms are classically thought to be suggestive of pertussis in children, but the diagnostic
value of these symptoms in adolescent and adult patients is unclear. We evaluated the accuracy of the clinical
findings for the early presumptive diagnosis of pertussis in adolescent and adult patients. Furthermore,
we measured fractional exhaled nitric oxide (FeNO) with regard to whether we could distinguish eosinophilic
inflammation of the airway and pertussis. FeNO is not expected to be associated with pertussis.
Methods: We compared 183 cases with laboratory-confirmed pertussis using serology and polymerase chain
reaction and 1,132 cases without laboratory-confirmed pertussis.
Results: Among pertussis patients, paroxysmal cough was common with 90% sensitivity, but the specificity was
low (25%). Posttussive vomiting and whoop were less common (sensitivity 25% and 19%, respectively), but both
showed greater specificity for pertussis (80% and 86%, respectively). Posttussive gagging was observed with
intermediate frequency and provided greater specificity (49% and 77%, respectively). Pertussis cases were
most frequent between May and August with a peak in June. The mean FeNO value for the pertussis patients was
18.2 ± 9.2 ppb, which was significantly lower than that in asthma patients (56.9 ± 20.3 ppb, p <0.001). The most
useful definition was posttussive vomiting and/or gagging, and a plus normal FeNO value, which had a sensitivity
of 72% and a specificity of 70%.
Conclusions: Clinical symptoms and laboratory data are of limited value in making the diagnosis of pertussis, and it
was clinically difficult to differentiate adolescent and adult patients with or without pertussis. However, pertussis
should be considered if patients have posttussive vomiting and/or gagging and a normal FeNO concentration.
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Background
There has been a change in the age-related epidemiology
of pertussis with an increasing proportion of cases re-
ported among adolescent and adult patients in the
United States, Canada, France and Australia, which all
have longstanding vaccine-induced pertussis control [1].
A number of studies have documented that between
13% and 32% of adolescent and adult patients with an
illness involving a cough of 6 days’ duration or longer
have serologic evidence of pertussis [2-6]. However, per-
tussis in adults may be overlooked, because symptoms
are often atypical, patients tend to present for medical
attention after they have been coughing for some time,
and nasopharyngeal cultures rarely are found to be posi-
tive. In addition, residual immunity from prior vacci-
nation may modify the clinical presentation of pertussis
in adolescent and adult patients, making the diagnosis
even more difficult.
Rapid and simple diagnostic tests are useful tools in
the early presumptive diagnosis of respiratory tract in-
fections (RTI) caused by some pathogens. These results
can be used to initiate appropriate antibiotic treatment
and prevent outbreaks. The most widely used and
quickest diagnostic method is the evaluation made by a
physician based on clinical and laboratory findings. Se-
veral symptoms, such as paroxysmal cough, posttussive
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vomiting and inspiratory whoop are classically thought
to be suggestive of pertussis in children [2], but the diag-
nostic value of each of these symptoms is uncertain in
adolescent and adult patients. Relatively few studies have
assessed the sensitivity and specificity of these classical
symptoms [7]. The purpose of the present study was to
identify a means of rapidly distinguishing pertussis from
other causes of illness involving cough in daily clinical
practice without waiting for serological or culture re-
sults. We evaluated the accuracy of the clinical findings
for the early presumptive diagnosis of pertussis in ado-
lescent and adult patients. Asthma and cough variant
asthma are the leading causes of persistent and chronic
cough and are thought to be the most important causes
in the differential diagnosis of cough illness [8-10]. Be-
cause the measurement of fractional exhaled nitric oxide
(FeNO) which reflects eosinophilic inflammation of the
airway is simple, rapid, non-invasive and easy to perform
and is characterized by high reproducibility, it may be
considered as a good candidate for a screening test in
the diagnosis of asthma and asthma-like syndromes
[11,12]. To exclude the eosinophilic inflammation of the
airway in daily clinical practice, we measured the FeNO
concentration with regard to whether we could distin-
guish asthma and pertussis patients.
Methods
Study populations
Adolescent and adult patients with cough symptoms
who visited Kawasaki Medical School Hospital, Kawasaki
Medical School Kawasaki Hospital and Kurashiki Daiichi
Hospital, from April 2005 to March 2012 were enrolled
in this study. Underlying conditions that induce cough,
especially chronic lung diseases, might influence the
symptoms and laboratory data for pertussis in adolescent
and adult patients. Thus, patients taking angiotensin-
converting enzyme inhibitors or with known or suspected
immunodeficiency, lung cancer, pneumonia, tuberculosis,
non-tuberculous mycobacterial disease, influenza, chronic
obstructive pulmonary diseases, bronchiectesis, diffuse
panbronchiolitis, interstitial lung diseases, chronic sinu-
sitis, gastroesophageal reflux, allergic rhinorhitis or
asthma were excluded. Control subjects without com-
plaints of cough were selected from healthy blood donors
during the study period [13].
Determination of FeNO has been suggested to have a
useful role in the evaluation of patients with chronic
cough [14-16]. This study was conducted as part of cough
studies investigating the usefulness of FeNO measurement
for the differentiation of cough illness. FeNO was mea-
sured in pertussis patients and in age- and gender-matched
healthy subjects who were selected from the medical staff
and patients with asthma who regularly visited our hos-
pital. A definitive diagnosis of bronchial asthma and cough
variant asthma was made by a respiratory specialist in the
outpatient clinic based on respiratory function, bronchial
responsiveness, blood tests and treatment course in ac-
cordance with the Global Initiative for Asthma guidelines
[17]. Informed consent was obtained from all patients, and
the study protocol was approved by the Ethics Committee
at Kawasaki Medical School.
We used a standardized questionnaire for collecting
clinical information. Information on patient background,
clinical signs and symptoms collected included paroxys-
mal cough, posttussive vomiting, posttussive gagging, in-
spiratory whoop, nocturnal cough, sputum production,
chest pain, dyspnea, history of fever, upper RTI symp-
toms (sneeze, sore throat, nasal mucus, nasal congestion
and headache) and history of cough in family members
or work/school colleagues.
Microbiological laboratory tests
Microbiological tests, such as Gram stain, cultures, real-
time polymerase chain reaction (PCR) and serological
tests, were performed as described previously [6,18].
Nasopharyngeal swab specimens were obtained from all
patients and, if sputum was available, a Gram stain test,
a quantitative culture and PCR were obtained. All naso-
pharyngeal swab specimens and sputum samples were
also used for PCR and culturing. The target DNA se-
quences for PCR were a region of the insertion sequence
IS481 for B. pertussis [19], region of the 53-kDa gene for
C. pneumoniae, the major outer membrane gene for
Chlamydia, the P1 cytadhesin gene for M. pneumoniae,
and the nucleotide sequence of the 5S-ribosomal DNA
for Legionella. DNA was extracted from respiratory sam-
ples using a QIAamp DNA Mini Kit (QIAGEN K. K.,
Tokyo, Japan) in accordance with the manufacturer’s
instructions. The assays were performed as described
previously [6,18,20]. Cultures for M. pneumoniae and
Legionella species were performed on pleuropneumonia-
like organism broth (Difco, Detroit, MI, USA) and buff-
ered charcoal-yeast extract alpha agar, respectively. Cul-
tures for Chlamydophila pneumoniae and C. psittaci
were performed using cycloheximide-treated HEp-2 cells
grown in a 24-well cell culture plate [6]. All specimens
were examined twice. Culture confirmation was done by
fluorescent-antibody staining with C. pneumoniae and
C. psittaci species-specific and genus-specific monoclo-
nal antibodies [6]. When physicians suspected influenza,
nasopharyngeal swab specimens were also tested for influ-
enza A and B viruses by a direct enzyme immunoassay.
Paired serum samples were collected at intervals of at least
4 weeks after onset. Serum samples were tested for anti-
bodies to B. pertussis pertussis toxin (PT) using an enzyme-
linked immunosorbent assay method (Wako Chemicals,
Tokyo, Japan) [21]. Antibodies against M. pneumoniae were
measured with the use of a particle agglutination (PA)
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test (Serodia-Myco II kit, Fujirebio, Tokyo, Japan), Legion-
ella species by a microagglutination test (detection of L.
pneumophila serogroups 1 ~ 6, L. bozemanii, L. dumoffii, L.
gormanii, and L. micdadei), Coxiella burnetii by an indirect
immunofluorescence test, and viruses (influenza A and B
viruses, adenovirus, respiratory syncytial virus, cytomegalo-
virus, and parainfluenza virus types 1, 2, and 3) by a com-
plement fixation test. A microimmunofluorescence test was
used for the titration of IgG and IgM antibodies against
chlamydial species using formalinized elementary bodies of
C. pneumoniae KKpn-15, C. trachomatis L2/434/Bu,
and C. psittaci Budgerigar-1 strains as antigens [6]. Rheuma-
toid factors were absorbed with GullSORB (Meridian
Bioscience Inc., OH, USA) before IgM titration.
Criteria for the determination of microbial etiology
The microbial etiology was classified as “definitive”, “pre-
sumptive”, or “unknown” as reported previously [18]. A
definitive etiology was recorded if one of the following
conditions was present: (1) respiratory specimen culture
or PCR results positive for M. pneumoniae, C. psittaci or
Legionella species; (2) a fourfold increase in the antibody
titer for viruses, M. pneumoniae (to ≥1:160), Legionella
species (to ≥1:128), C. burnetii, or Chlamydia species
(IgM or IgG); (3) a single increase in IgM titer for
Chlamydia species ≥1:32; or (4) nasopharyngeal antigen
test results positive for influenza A and B viruses. A pre-
sumptive etiology was considered if any of the following
conditions were present: (1) an organism showing heavy
(≥107 cfu/mL) or moderate (106 cfu/mL) growth of a
predominant bacterium on a sputum culture in combi-
nation with Gram stain findings; (2) an antibody titer of
≥1:320 for M. pneumoniae in either an acute-phase or
convalescent-phase serum samples; (3) an antibody titer of
≥1:256 for Legionella species in either an acute-phase or
convalescent-phase serum samples; or (4) respiratory spe-
cimen culture or PCR results positive for C. pneumoniae.
Laboratory confirmation of recent infection with B.
pertussis was defined if one of the following conditions
was present: (1) a fourfold increase in anti-PT antibody;
(2) a single serum anti-PT titer more than 3 standard
deviations (SD) greater than the geometric mean of age-
matched control values in either an acute-phase or
convalescent-phase serum sample; or (3) nasopharyngeal
swab PCR assay result positive. Using the criterion for
the titer of a single PT antibody of ≥3 SD of the mean of
318 age-matched control values, the present results
demonstrated that a level of ≥100 EU/mL defined a re-
cent pertussis infection.
Measurement of FeNO
The concentration of nitric oxide (NO) in expired air was
evaluated on-line using a chemiluminescence analyzer NOA
280i (Sievers Instruments, Inc, USA). The measurement
conditions of the on-line method were set in
accordance with the American Thoracic Society and the
European Respiratory Society guidelines [22]. From patients
resting in a sitting position, expired gas after maximum in-
spiration was collected in a Mylar bag at an expiratory re-
sistance of 5 cm H2O or higher and expiratory flow rate of
0.35 L/sec (0.315 - 0.385 L/sec). The measurement was
performed in triplicate, and the mean was adopted.
Statistical analysis
Statistical analysis was performed using Stat View version
5.0. (SAS Institute Inc, Cary, NC, USA). The incidence of
clinical findings of patients with and without laboratory
evidence of pertussis was compared using Fisher’s exact
test. The mean age of patients, laboratory data and FeNO
value were compared using Student’s t test.
Results
Patient characteristics
During the study period, 7,112 patients visited our hos-
pital for the complaint of cough and 4,125 were excluded
according to the exclusion criteria. Of the remaining 2,987
patients, physicians could not follow-up or could not carry
out all microbiological tests in 1,662 patients. Finally,
1,325 patients were assessed using all the microbiological
tests described in the Methods section. Cough duration of
these patients at first visit was 3 to 21 days after onset of
disease (mean 14.1 days). Among these cough patients,
we excluded from the analysis 10 cases of mixed-pertussis
infection with other pathogens. Finally, we enrolled and
analyzed 183 cases of laboratory-confirmed pertussis. Of
these, 36 cases demonstrated a fourfold increase in anti-
body titer (16 cases were PCR positive), and 125 cases
demonstrated a single serum titer ≥3 SD above the mean
of the control values, and 41 cases were PCR positive
(19 cases were positive for both tests).
Table 1 shows the characteristics of the patients with
and without laboratory-confirmed pertussis. No signifi-
cant differences in age or gender were identified between
the two groups, but patients with laboratory-confirmed
pertussis were more likely to have paroxysmal cough,
posttussive gagging and inspiratory whoop. The proportion
of patients with a family member or work/school colleague
with a coughing illness differed between the laboratory-
confirmed pertussis and no laboratory-confirmed pertussis
groups (53% vs 24%, p <0.0001). No significant differences
in laboratory data were found between the two groups, and
mean WBC and mean lymphocyte counts were normal in
both groups.
Differentiation among laboratory-confirmed pathogens
Among the patients without laboratory-confirmed pertus-
sis, other pathogens were established in 252 cases.
M. pneumoniae was detected in 105 cases, C. pneumoniae
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in 93 cases, viruses in 52 cases and bacteria in 12 cases.
Among viruses, influenza was excluded in this study be-
cause the clinical presentation of influenza is clearly diffe-
rent from respiratory infections with other pathogens. No
cases with C. psittaci, C. burnetii, or Legionella species were
detected. Among the M. pneumoniae cases, three were cul-
ture positive, 86 were PCR positive, and 43 demonstrated
positive serological results (27 cases were positive for two
methods). Among the C. pneumoniae cases, 59 were PCR
positive and 42 demonstrated positive serological results
(eight cases were positive for both methods).
Table 2 shows the characteristics of the patients with
laboratory-confirmed pertussis, M. pneumoniae, C. pneu-
moniae, viruses and mixed-pertussis infection with other
pathogens: C. pneumoniae (one case), M. pneumoniae
(one case), S. pneumoniae (one cases), Moraxella
catarrhalis (one case), and viruses (six cases). Characteris-
tics were almost identical among patients with pertussis,
M. pneumoniae, C. pneumoniae, and mixed-pertussis in-
fection with other pathogens but patients with laboratory-
confirmed pertussis were more likely to have posttussive
gagging and inspiratory whoop. In contrast, many signifi-
cant differences were observed between the laboratory-
confirmed pertussis and viruses patients.
Seasonality
During the period between 2005 and 2012, the average
monthly number of sera and nasopharyngeal swabs sub-
mitted for serology and PCR was highest during the
winter months of December through February. In con-
trast, positive pertussis cases were most frequent during
the months May through August with a peak in June
(Figure 1). Although annual fluctuations in the number
of samples tested and the number of positive pertussis
cases was observed during the study period, the peaks
of pertussis cases were distributed between May and July
in each year.
FeNO concentration
We started the measurement of FeNO concentrations
from 2007 routinely. Thus, we measured FeNO concen-
trations in 112 pertussis patients and compared these
with 112 healthy volunteers and 112 asthma patients.
The mean FeNO value for the pertussis patients was
18.2 ± 9.2 ppb. This value was significantly lower than
that in asthma patients (56.9 ± 20.3 ppb, p <0.001) but
not significantly different from that in healthy volunteers
(16.4 ± 6.8 ppb, p = 0.2181).
Discussion
There is increasing appreciation of pertussis as an
unrecognized but important cause of prolonged cough
illness in older age groups. In terms of the clinical symp-
toms of pertussis in adolescents and adults, De Serres
et al. published data on the symptoms of 664 cases [23].
Among classic pertussis symptoms, the most common
symptoms were paroxysmal cough (99%), next to post-
tussive apnea (87%), whoop (69%) and posttussive
vomiting (65%). Von Koenig et al. reviewed symptoms
described in studies in adult patients [3]. Although, the
incidence of paroxysmal cough was similar among stu-
dies and ranged from 70% to 99%, whoop and posttussive
vomiting exhibited wide variations with ranges from 8%
to 82% and 17% to 65%, respectively. Subsequently,
Rothstein and Edwards reviewed symptoms described in
studies into health burden in adults [4]. Studies suggest
that between 21% and 86% of adults have classic pertussis
symptoms such as paroxysmal cough, whoop and
posttussive vomiting.
Today, many different case definitions are used through-
out the world. Ghanaie et al. studied the sensitivity and
specificity of the WHO pertussis clinical case definitions
in 328 children aged 6 to 14 years with persistent cough
for ≥2 weeks [24]. The sensitivity was 95.2% and the speci-
ficity was 15.0% with cough ≥2 weeks plus one of the










Age mean (range), years 39.1 (16–77) 37.6 (16–79) 0.3189
Male : Female 73 : 110 501 : 631 0.2965
Symptom*
Paroxysmal cough 165 (90.1) 849 (75.0) <0.0001
Awakened by cough 133 (72.6) 747 (65.9) 0.0760
Sputum production 67 (36.6) 378 (33.3) 0.4006
Chest pain 66 (36.0) 382 (33.7) 0.5566
Dyspnea 56 (30.6) 297 (26.2) 0.2423
Posttussive vomiting 46 (25.1) 228 (20.1) 0.1407
Posttussive gagging 90 (49.1) 259 (22.8) <0.0001
Inspiratory whoop 36 (19.6) 156 (13.7) 0.0420




83 (45.3) 561 (49.5) 0.3011
Exposed to cough by family
member or work/school
colleague*
97 (53.0) 273 (24.1) <0.0001
Hospitalization* 1 (0.5) 10 (0.8) >0.9999
Laboratory data
WBC mean
number ± SD, /mm3
6,619 ± 2,815 7,034 ± 2,622 0.1925
Lymphocyte mean
number ± SD, /mm3
2,043 ± 892 2,211 ± 973 0.1244
*Data represent the numbers (%) of patients.
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WHO clinical criteria. With an increasing number of
clinical findings, sensitivity decreased and specificity in-
creased. Posttussive vomiting was the symptom that had
the most pronounced effect in increasing specificity. In a
study of pertussis in adolescents and adults by Strebel
et al. [5], the sensitivity and specificity of paroxysmal
cough were 100% and 12%, respectively. With posttussive
vomiting, the sensitivity was 56% and the specificity was
68%; for whooping, the sensitivity was 28% and the speci-
ficity was 85%. In 1988, Patriarca et al. evaluated 15 cli-
nical case definitions for pertussis during community
outbreaks and concluded that a definition of ≥2 weeks of
cough was both sensitive (77–91%) and specific (54–71%)
for monitoring culture-positive cases [25]. However, in
nonoutbreak situations, the use of their case definitions
had low sensitivity [26].
Among our adolescent and adult patients with pertus-
sis, paroxysmal cough was common with 90% sensitivity,
but the specificity of this finding was low (25%). Post-
tussive vomiting and whoop were less common (sensiti-
vity 25% and 19%, respectively), but both showed greater
specificity for pertussis infection (80% and 86%, respec-
tively). Strebel et al. indicated that pertussis should be
considered in the differential diagnosis of acute cough
illness in adolescent and adult patients, especially if the
cough is associated with posttussive vomiting and/or
gagging [5]. Our results also demonstrated that patients
with laboratory-confirmed pertussis were more likely to
have a history of posttussive gagging, but the sensitivity
was intermediate (sensitivity: 49%; specificity: 77%). Ex-
posure history of coughing is one tool to differentiate
Table 2 Characteristics of patients with laboratory-confirmed pertussis, M. pneumoniae, C. pneumoniae, viruses and
mixed-pertussis infection with other pathogens
Characteristics Pertussis M. pneumoniae C. pneumoniae Viruses Mixed-pertussis infection*
Number 183 105 93 52 10
Age mean (range), years 39.1 (16–77) 35.2 (16–46) 36.4 (18–52) 39.4 (24–76) 39.7 (27–65)
Male : Female 73 : 110 49 : 56 45 : 48 25 : 27 5 : 5
Symptom**
Paroxysmal cough 165 (90.1) 89 (84.7) 68 (73.1)*** 24 (46.1)*** 100 (100.0)
Awakened by cough 133 (72.6) 84 (80.0) 66 (70.9) 29 (55.7)*** 9 (90.0)
Sputum production 67 (36.6) 40 (38.0) 30 (32.2) 17 (32.6) 5 (50.0)
Chest pain 66 (36.0) 38 (36.1) 25 (26.8) 12 (23.0) 3 (30.0)
Dyspnea 56 (30.6) 30 (28.5) 21 (22.5) 6 (11.5)*** 4 (40.0)
Posttussive vomiting 46 (25.1) 20 (19.0) 15 (16.1) 0 *** 2 (20.0)
Posttussive gagging 90 (49.1) 32 (30.4)*** 22 (23.6)*** 6 (11.5)*** 6 (60.0)
Inspiratory whoop 36 (19.6) 11 (10.4)*** 10 (10.7)*** 0*** 1 (10.0)
History of fever (≥37.0°C) 27 (14.7) 35 (33.3)*** 8 (8.6) 19 (36.5)*** 50 (50.0)***
Upper respiratory tract infection
symptoms before cough
83 (45.3) 55 (52.3) 37 (39.7) 45 (86.5)*** 8 (80.0)***
Exposed to cough by family
member or work/school colleague**
97 (53.0) 49 (46.6) 40 (43.0) 26 (50.0) 60 (60.0)
Hospitalization** 1 (0.5) 1 (0.9) 0 0 1 (10.0)
Laboratory data
WBC mean number ± SD, /mm3 6,619 ± 2,815 6,249 ± 2,731 6,972 ± 2,618 6,314 ± 2,765 6,898 ± 2,265
Lymphocyte mean number ± SD, /mm3 2,043 ± 892 1,986 ± 878 2,361 ± 958 2,419 ± 954 2,133 ± 854
* Mixed-pertussis infection with other pathogens: Chlamydophila pneumoniae (one case), Mycoplasma pneumoniae (one case), Streptococcus pneumoniae
(one cases), Moraxella catarrhalis (one case) and viruses (six cases).
** Data represent the numbers (%) of patients.





Figure 1 Cases of pertussis in adolescent and adult patients by
month between 2005 and 2012.
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patients with pertussis from those without the disease
but sensitivity was intermediate (sensitivity: 53%; specifi-
city: 76%). Our results together with the results of previ-
ous studies suggest that individual symptoms may be of
limited help in distinguishing pertussis from other causes
of cough [5,27].
To improve pertussis diagnosis, the Global Pertussis
Initiative suggested a different approach [28]. They deve-
loped an algorithm that delineates the signs/symptoms of
pertussis most common to three age groups: 0–3 months,
4 months to 9 years, and ≥10 years. In patients ≥10 years
of age, the presence of a worsening paroxysmal, nonpro-
ductive cough of ≥7 days’ duration while afebrile but with
coryza that has not become purulent would also indicate
high sensitivity and good specificity for pertussis. In
addition, the presence of sweating episodes between par-
oxysms significantly increase specificity. Determination of
their utility and their sensitivity and specificity versus
existing case definitions is required.
Seasonal increases are a common phenomenon in in-
fectious diseases, but the underlying mechanisms are
not entirely clear [29]. For respiratory pathogens, sea-
sonal increases are thought to be driven by seasonal
variations in survival of the pathogen outside the host,
host behavior and the level of host immunity. Several
studies have reported that pertussis has seasonality, with
activity generally peaking in August [30,31] or between
the early summer and early autumn [5,32,33]. Our study
during the past 7 years demonstrated a clear seasonal
pattern in the incidence of reported cases, with many
cases occurring between May and August each year. Per-
tussis is specified for weekly reporting by specially desig-
nated sentinel pediatric clinics in accordance with the
Japanese Infectious Diseases Control Law [34]. The same
seasonal observations with peaks between May and July
were reported in pediatric patients during the past decade
[35]. In contrast to Western countries, April is the start of
the school year for schools and universities in Japan. In
several recent years, many outbreaks in schools and uni-
versities occurred between May and July [20,35]. Thus,
the starting of schools and universities may play a role in
seasonal increases in the incidence of pertussis in Japan.
To improve the diagnostic accuracy, we assessed the
use of combinations of symptoms and other findings.
The most useful combination definition was posttussive
vomiting and/or gagging, and a normal FeNO value,
which had a sensitivity of 72% and a specificity of 70%.
The combination of symptoms and laboratory findings
may be slightly more helpful.
Our study had several limitations. One of the serious
concerns about our study is the exclusion of large number
of patients with underlying diseases that caused persistent
cough. Unfortunately, we did not perform microbiological
tests in these excluded patients. However, pertussis could
be present in these groups and data on the performance
of the tests in these patients would be useful. Thus, fur-
ther evaluation, including larger sample sizes with under-
lying diseases and cough patients, is necessary. Another
limitation was that we did not carry out culture because
several studies demonstrated the sensitivity of culture
in adolescent and adult patients was extremely low.
Thus, we used PCR instead of culture for the diagnosis of
B. pertussis. In addition, the sample size for patients with
laboratory-confirmed viruses was too small. In this study,
we used only serological tests to identify viruses, thus,
further studies including larger sample sizes of cough
patients due to viruses identified using culture and PCR
are necessary.
Conclusions
We found a clear seasonal pattern in the occurrence of
pertussis cases in adolescent and adult patients. Clinical
symptoms and laboratory data were of limited value in
making the diagnosis of pertussis and it was clinically diffi-
cult to differentiate patients with pertussis from those
without the disease in adolescent and adult patients. How-
ever, cough is a common symptom and is treated symp-
tomatically without a definitive diagnosis. Thus, pertussis
should be considered in the differential diagnosis of cough
illness in adolescent and adult patients, especially if the
patient has posttussive vomiting and/or gagging and nor-
mal FeNO concentration.
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